These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12186156)

  • 1. Hyperhomocysteinemia and vascular disease: role and implications.
    Yeolekar ME; Bichile SK; Shete MM
    J Assoc Physicians India; 2002 May; 50 Suppl():5-8. PubMed ID: 12186156
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging cardiovascular risk factors in end-stage renal disease.
    Yaqoob MM
    J Nephrol; 2002; 15(2):205-8. PubMed ID: 12018642
    [No Abstract]   [Full Text] [Related]  

  • 3. Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences.
    Perna AF; Capasso R; Acanfora F; Satta E; Lombardi C; Ingrosso D; Violetti E; Romano MM; De Santo NG
    Semin Nephrol; 2006 Jan; 26(1):20-3. PubMed ID: 16412820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus.
    Suliman ME; Stenvinkel P; Bárány P; Heimbürger O; Anderstam B; Lindholm B
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S89-95. PubMed ID: 12612961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homocysteine is not so paradoxical.
    Klevay LM
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):e160; author reply e161. PubMed ID: 18799792
    [No Abstract]   [Full Text] [Related]  

  • 6. Vitamins and prevention of cardiovascular disease and cancer: should we give supplements?
    Alpers DH
    Curr Opin Gastroenterol; 2007 Mar; 23(2):159-63. PubMed ID: 17268244
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hyperhomocysteinemia as a risk factor for cardiovascular diseases in patients with chronic renal failure].
    Małecki R
    Pol Arch Med Wewn; 2000 Oct; 104(4):695-701. PubMed ID: 11392158
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients.
    Righetti M; Ferrario GM; Milani S; Serbelloni P; La Rosa L; Uccellini M; Sessa A
    Med Sci Monit; 2003 Apr; 9(4):PI19-24. PubMed ID: 12709680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design for the CARDIOVIT Study (Cardiovit, Atherosclerotic vascular disease and hypeRhomocysteinemia: an epiDemiological study in Indians, additionally evaluating the effect of Oral VITamin supplementation).
    Shenoy KT; Lena KB; Sali N; Syam S; Shenoy ST; Rajadhyaksha VD; Pai GP; Shaikh AA;
    Curr Med Res Opin; 2006 Apr; 22(4):641-8. PubMed ID: 16684424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk factors for cardiovascular diseases: what is the role for homocysteine?].
    Bendini MG; Lanza GA; Mazza A; Giordano A; Leggio M; Menichini G; De Cristofaro R; Moriconi E; Cozzari L; Farina SM; Giordano G
    G Ital Cardiol (Rome); 2007 Mar; 8(3):148-60. PubMed ID: 17461357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal insufficiency is an important cardiovascular risk factor].
    Pérez Flores I; Luño J
    Nefrologia; 2002; 22(4):306-9. PubMed ID: 12369120
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cellular and molecular mechanism of cardiovascular disease resulting from hyperhomocysteinemia].
    Gao L; Tang CS
    Sheng Li Ke Xue Jin Zhan; 2002 Oct; 33(4):335-8. PubMed ID: 12650071
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
    Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
    Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Homocysteine and rheumatic disease].
    Tinazzi I; Caramaschi P; Patuzzo G; Bambara LM; Biasi D
    Recenti Prog Med; 2007 Dec; 98(12):646-52. PubMed ID: 18369042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperhomocysteinemia and advancement of atherosclerosis in patients with chronic renal failure on maintenance hemodialysis].
    Sydor A; Drozdz M; Kraśniak A; Miłkowski A; Chmiel G; Małczak J; Zabawa-Hołyś S; Moskal K; Podwysocki A; Szmigielski M; Czarnecka D; Gozdecka H; Kowalczyk-Michałek M; Szczeklik A; Wiecek A; Sułowicz W
    Przegl Lek; 2002; 59(12):962-7. PubMed ID: 12731367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperhomocysteinemia as a risk factor for cardiovascular diseases].
    Kovaćević G; Andrejević-Kovaćević S; Kostić G; Novak A
    Srp Arh Celok Lek; 2000; 128(11-12):403-8. PubMed ID: 11337922
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prevalence of hyperhomocysteinemia and related factors in a community-based health examination survey: a cross-sectional study].
    Kim SJ; Lim KS; Song MS; Kang Y; Lee SY
    J Prev Med Public Health; 2009 Sep; 42(5):337-42. PubMed ID: 19806007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Consequences of moderate hyperhomocysteinemia in internal medicine].
    Zák A; Zeman M
    Cas Lek Cesk; 2004; 143(6):367-74. PubMed ID: 15309862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism.
    De Caterina R; Zampolli A; Madonna R; Fioretti P; Vanuzzo D
    Ital Heart J; 2004 Jun; 5 Suppl 6():19S-24S. PubMed ID: 15185912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.